Cited by 2,003Bone health and osteoporosis researchBone health and treatmentsHip and Femur Fractures

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Open access

Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven·2007·New England Journal of Medicine

DOI 10.1056/nejmoa074941PMC PMC2324066

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa074941

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vitamin D Deficiency
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281

Show all 35 references

Research works printed but not linked: 2

Davidson CW, 2001, N Z Med J, 114, 329
2003, World Health Organ Tech Rep Ser, 921, 1

Sorted by citations

Items 901–1,000 of 1,000

Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision
Alzahouri, K., Bahrami, S., Durand‐Zaleski, I., Guillemin, F., & Roux, C. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.01.001 · Cited by 15
Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases
Boonen, S., Kay, R., Cooper, C. C., Haentjens, P., Vanderschueren, D., Callewaert, F., Milisen, K., & Ferrari, S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02206.x · Cited by 15
Self-citation
Management of Osteoporosis in Older People
Inderjeeth, C. A., & Poland, K. E. (2010) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2010.tb00545.x · Cited by 15
The rate of hip osteoarthritis in patients with proximal femoral fractures versus hip contusion
Robstad, B., Frihagen, F., & Nordsletten, L. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1628-8 · Cited by 15
Self-citation
Fracture Risk Assessment: From Population to Individual
Nguyen, T. V., & Eisman, J. A. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.023 · Cited by 15
Grundlagen der Knochenbruchheilung
Rausch, V., Seybold, D., Königshausen, M., Köller, M., Schildhauer, T. A., & Geßmann, J. (2017) · Der Orthopäde · doi:10.1007/s00132-017-3449-8 · Cited by 15
Bisphosphonate use after clinical fracture and risk of new fracture
Bergman, J., Nordström, A., & Nordström, P. (2018) · Osteoporosis International · doi:10.1007/s00198-017-4367-7 · Cited by 15
Effect of Preoperative Bisphosphonate Treatment on Fracture Healing after Internal Fixation Treatment of Intertrochanteric Femoral Fractures
Lim, E. J., Kim, J.-T., Kim, C., Kim, J. W., Chang, J. S., & Yoon, P. W. (2019) · Hip & Pelvis · doi:10.5371/hp.2019.31.2.75 · Cited by 15
Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Rodríguez, A. J., & Abrahamsen, B. (2021) · JBMR Plus · doi:10.1002/jbm4.10522 · Cited by 15
Elastomer femoroplasty prevents hip fracture displacement
van der Steenhoven, T. J., Schaasberg, W., de Vries, A. C., Valstar, E. R., & Nelissen, R. G. H. H. (2011) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2010.12.009 · Cited by 15
Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic
Craig, S. J., Youssef, P. P., Vaile, J. H., Sullivan, L., & Bleasel, J. F. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2010.02198.x · Cited by 15
Ibandronate
Frampton, J. E., & Perry, C. M. (2008) · Drugs · doi:10.2165/0003495-200868180-00011 · Cited by 15
Once-yearly zoledronic acid in hip fracture prevention
Duque, G., & Demontiero (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s5065 · Cited by 15
No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site
Biver, E., Vieillard, M.-H., Cortet, B., Salleron, J., Falgayrac, G., & Penel, G. (2009) · Bone · doi:10.1016/j.bone.2009.10.034 · Cited by 15
Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects
Michalak, F., Hnitecka, S., Dominiak, M., & Grzech‐Leśniak, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030354 · Cited by 14
Efficacy of Antiresorptive Treatment in Osteoporotic Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Cedeño‐Veloz, B. A., Erviti, J., Gutiérrez‐Valencia, M., Leache, L., Saiz, L. C., García, A. M. R., Latorre, M. S., Ramírez‐Vélez, R., Izquierdo, M., & Martínez‐Velilla, N. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1825-5 · Cited by 14
A novel fracture liaison service using digital health: impact on mortality in hospitalized elderly osteoporotic fracture patients
Lü, K., Wu, Y.-M., Shi, Q., Gong, Y.-Q., Zhang, T., & Li, C. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06905-5 · Cited by 15
Declining hip fracture burden in Sweden 1998–2019 and consequences for projections through 2050
Michaëlsson, K., Baron, J. A., Byberg, L., Larsson, S. C., Melhus, H., & Gedeborg, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-51363-6 · Cited by 14
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials
Lane, J. M., Langdahl, B. L., Stone, M. D., Kurth, A., Oates, M. K., Timoshanko, J., Wang, Z., Libanati, C. R., & Cosman, F. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07049-w · Cited by 14
The Patient with Hip Fracture
Rudy, M. D., & Grant, P. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.04.004 · Cited by 14
Inpatient zoledronic acid in older hip fracture patients is well tolerated and safe
Malgo, F., van Deudekom, F. J. A., Hup, R., Jonkers, H. A. F., Kempen, D. H. R., de Vries, K., Willems, H. C., & Veldhuis‐Vlug, A. G. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01453-9 · Cited by 14
Update on the Comprehensive Approach to Fragility Fractures
Cohn, M. R., Gianakos, A. L., Grueter, K., Rosen, N. S., Cong, T., & Lane, J. M. (2018) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001244 · Cited by 14
Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy
Kirchmayer, U., Sorge, C., Sultana, J., Lapi, F., Onder, G., Agabiti, N., Cascini, S., Roberto, G., Corrao, G., Vitale, C., et al. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619838138 · Cited by 14
Team Approach: Multidisciplinary Treatment of Hip Fractures in Elderly Patients
Figved, W., Myrstad, M., Saltvedt, I. T., Finjarn, M., Odland, L. M. F., & Frihagen, F. (2019) · JBJS Reviews · doi:10.2106/jbjs.rvw.18.00136 · Cited by 14
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial
Lima, T. B., Santos, L. A. A., Nunes, H. R. D. C., Silva, G. F., Caramori, C. A., Qi, X., & Romeiro, F. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-55603-y · Cited by 14
Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan
CHEN, Y., Kung, P., Chou, W., & Tsai, W. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05399-9 · Cited by 14
Osteoporosis
Sinaki, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-62539-5.00034-5 · Cited by 14
Expected Benefits and Budget Impact From a Microsimulation Model Support the Prioritization and Implementation of Fracture Liaison Services
Pinedo‐Villanueva, R., Burn, E., Maronga, C., Cooper, C. C., & Javaid, M. K. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4775 · Cited by 14
Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture
Warriner, A. H., Outman, R. C., Saag, K. G., Berry, S. D., Colon-Emeric, C. S., Flood, K. L., Lyles, K. W., Tanner, S. B., Watts, N. B., & Curtis, J. R. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819bc1d3 · Cited by 14
Self-citation
Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions
Beaupré, L. A., Majumdar, S. R., Dieleman, S., Au, A. G., & Morrish, D. W. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1582-5 · Cited by 14
Osteoporosis in older persons: current pharmacotherapy and future directions
Duque, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.822861 · Cited by 14
Bone health in women with breast cancer
Ramchand, S. K., Cheung, Y.-M. M., & Grossmann, M. (2019) · Climacteric · doi:10.1080/13697137.2019.1580257 · Cited by 14
The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study
Oleson, C. V., Marino, R. J., Formal, C. S., Modlesky, C. M., & Leiby, B. E. (2020) · Spinal Cord · doi:10.1038/s41393-020-0431-9 · Cited by 14
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
Sunyecz, J. A. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2496 · Cited by 14
Mortalidade após fratura por osteoporose
Pinheiro, M. A. A. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000700001 · Cited by 14
Osteoporosis en el varón
Moro-Álvarez, M. J., & Cabrera, J. A. B. (2010) · Revista Clínica Española · doi:10.1016/j.rce.2009.11.023 · Cited by 14
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin, E. J., & Raehl, C. L. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070302 · Cited by 14
Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface
Sebba, A. I. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0802-0 · Cited by 14
Bisphosphonates for Postmenopausal Osteoporosis
Giusti, A., & Papapoulos, S. E. (2018) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9781119266594.ch71 · Cited by 14
Revisión sistemática de la literatura sobre la osteonecrosis maxilar con el uso de bisfosfonatos en pacientes con osteoporosis
Carmona, E. C., Flores, A. G., Loza, E., Olea, A. H., & Lozano, M. P. R. (2013) · Reumatología Clínica · doi:10.1016/j.reuma.2012.05.005 · Cited by 13
Trends in Hip Fracture-Related Mortality in Texas, 1990-2007
Orces, C. H., & Alamgir, A. H. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e31821e9a4d · Cited by 13
Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention
Bubbear, J. S. (2016) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10259 · Cited by 13
NHG-Standaard Fractuurpreventie (tweede herziening)
Elders, P. J. M., Dinant, G., van Geel, T. A. C. M., Maartens, L. W. F., Merlijn, T., Geijer, R. M. M., & Geraets, J. J. X. R. (2012) · Pure Amsterdam UMC · Cited by 13
Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly
Sáez-López, P., Etxebarría-Foronda, Í., Lampré, M. P. M., García, N. A., & Hernández, N. S. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2018.11.007 · Cited by 13
Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management
Jassim, N. A., Adib, G., Younis, A. A. R., Gorial, F. I., Maghraoui, A., Al-Suhaili, A. R., Murtaji, A., Otom, A. H., Masri, B. K., Saba, E., et al. (2017) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.28.1.27 · Cited by 13
The role of bisphosphonates in orthodontic tooth movement—A review
Ajwa, N. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_825_19 · Cited by 13
Meta-analysis for the efficacy of bisphosphonates on hip fracture prevention
Tsuda, T., Hashimoto, Y., Okamoto, Y., Ando, W., & Ebina, K. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01096-z · Cited by 13
Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis
Huang, X., Chen, B., Thabane, L., Adachi, J. D., & Li, G. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05865-y · Cited by 13
Self-citation
Is calcium a link between inflammatory bone resorption and heart disease?
Klein, G. L. (2022) · eLife · doi:10.7554/elife.83841 · Cited by 13
Evaluation and Management of Hip Fracture Risk in the Aged
Rubin, C. D., & Palmer, B. F. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182121034 · Cited by 13
Preventing falls and fractures in long-term care
Wallis, S., & Campbell, G. A. (2011) · Reviews in Clinical Gerontology · doi:10.1017/s0959259811000104 · Cited by 14
An Effective Team Approach to Improve Postoperative Hip Fracture Care
Piziak, V. K., & Rajab, M. H. (2011) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3181db703c · Cited by 13
Bisphosphonate-Related Osteonecrosis of Jaws in 3 Osteoporotic Patients With History of Oral Bisphosphonate Use Treated With Single Yearly Zoledronic Acid Infusion
Fitzpatrick, S. G., Stavropoulos, M. F., Bowers, L. M., Neuman, A. N., Hinkson, D. W., Green, J. G., Bhattacharyya, I., & Cohen, D. M. (2011) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.02.049 · Cited by 13
Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?
LUBWAMA, R. N., Nguyen, A. M., Modi, A., Diana, C., & Miller, P. D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2645-1 · Cited by 13
Fractures and mortality in relation to different osteoporosis treatments.
Yun, H., Delzell, E., Saag, K. G., Kilgore, M. L., Morrisey, M. A., Muntner, P., Matthews, R., Guo, L., Wright, N. C., Smith, W., et al. (2015) · PubMed · Cited by 13
Self-citation
Osteoporosis and Bone Biology
de Paula, F. J. A., Black, D. M., & Rosen, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00029-0 · Cited by 14
Difference in the trajectory of change in bone geometry as measured by hip structural analysis in the narrow neck, intertrochanteric region, and femoral shaft between men and women following hip fracture
Rathbun, A. M., Shardell, M. D., Orwig, D., Hebel, J. R., Hicks, G. E., Beck, T., Magaziner, J. S., & Hochberg, M. C. (2016) · Bone · doi:10.1016/j.bone.2016.08.020 · Cited by 13
Self-citation
Economic implications of osteoporotic fractures in postmenopausal women
Patel, J. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88549 · Cited by 13
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
Clarke, B. L. (2010) · Yearbook of Medicine · doi:10.1016/s0084-3873(10)79795-9 · Cited by 13
Indications to teriparatide treatment in patients with osteoporosis
Rizzoli, R., KRAENZLIN, M. E., & Lippuner, K. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13297 · Cited by 13
Individualized fracture risk assessment
Nguyen, T. V., & Eisman, J. A. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328361ff8c · Cited by 13
Intravenous zoledronate for osteoporosis: less might be more
Grey, A. B. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16650866 · Cited by 13
Bisphosphonate Use After Hip Fracture in Older Adults: A Nationwide Retrospective Cohort Study
Nordström, P., Toots, A., Gustafson, Y., Thorngren, K., Hommel, A., & Nordström, A. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.12.083 · Cited by 13
Primary osteoporosis in men: an unmet medical need
Mendoza, F. A., Roux, M. L., & Ahmed, I. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.003 · Cited by 13
Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
Iaquinto, G., Sorrentini, I., Petillo, F. E., & Berardesca, G. (1994) · PubMed · Cited by 13
Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures
Girgis, C. M., & Seibel, M. J. (2011) · Bone · doi:10.1016/j.bone.2011.02.013 · Cited by 13
Chemistry of Bisphosphonates
McKenna, C., Haratipour, P., Duro, M. V., & Ebetino, F. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11260-7 · Cited by 11
Management of postmenopausal osteoporosis
Reid, I. R., & Bolland, M. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag006 · Cited by 13
Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery
Kashii, M., Kamatani, T., Abe, S., Yoshida, A., Yamamoto, K., Koizumi, K., Mizuno, N., Kuriyama, K., & Yoshikawa, H. (2021) · Bone · doi:10.1016/j.bone.2021.116298 · Cited by 12
Biomechanical analysis of various internal fracture fixation devices used for treating femoral neck fractures: A comparative finite element analysis
Mahapatra, B., & Pal, B. (2024) · Injury · doi:10.1016/j.injury.2024.111717 · Cited by 12
Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials
Lan, Z., Lin, X., Xue, D., Yang, Y., Saad, M., & Jin, Q. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003204 · Cited by 12
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Adami, G., & Saag, K. G. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43179 · Cited by 12
Atrial fibrillation and the use of oral bisphosphonates
Pazianas, Cooper, C. C., Wang, Lange, & Russell, R. G. G. (2011) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s17899 · Cited by 12
Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial
Adachi, J. D., Lyles, K. W., Boonen, S., Colon-Emeric, C. S., Hyldstrup, L., Nordsletten, L., Pieper, C. F., Recknor, C. P., Su, G., Bucci-Rechtweg, C. M., et al. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9543-8 · Cited by 12
Self-citation
Atypical fractures of the femur related to prolonged treatment with bisphosphonates for osteoporosis.
Rosenthal, Y., Arami, A., Kosashvili, Y., Cohen, N., Sidon, E., & Velkes, S. (2014) · PubMed · Cited by 12
Improving shared decision-making for osteoporosis pharmacologic therapy in nursing homes: a qualitative analysis
Colon-Emeric, C. S., Hecker, E. J., McConnell, E. S., Herndon, L., Little, M. O., Xue, T., & Berry, S. D. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-021-01050-0 · Cited by 12
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
Shen, J., Ke, Z., Dong, S., Lv, M., Yuan, Y., Song, L., Wu, K., Xu, K., & Hu, Y. (2022) · Medical Science Monitor · doi:10.12659/msm.935491 · Cited by 12
Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
Silva, B. C. C., Madeira, M., d’Alva, C. B., Maeda, S. S., de Holanda, N. C. P., Ohe, M. N., Szejnfeld, V. L., Zerbini, C. A. F., de Paula, F. J. A., & Bandeira, F. A. F. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000522 · Cited by 12
Osteoporotic vertebral compression fractures caused by Cushing’s syndrome in young women: case report and literature review
Cheng, J., ju, S., & Zhang, Z. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06253-9 · Cited by 12
Management of osteoporosis in geriatric populations
Schneider, D. L. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0018-4 · Cited by 12
Multiple hydrogen bonds in cytosinium zoledronate trihydrate
Sridhar, B., & Ravikumar, K. (2011) · Acta Crystallographica Section C Crystal Structure Communications · doi:10.1107/s0108270111005191 · Cited by 12
Fracture prevention in men
Geusens, P., Sambrook, P. N., & Lems, W. F. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.148 · Cited by 12
Improving patients’ outcomes after osteoporotic fractures
Dimitriou, R. I., Calori, G. M., & Giannoudis, P. V. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.68 · Cited by 12
Duration of anti-resorptive therapy for osteoporosis
Adler, R. A. (2015) · Endocrine · doi:10.1007/s12020-015-0748-x · Cited by 12
Trends in the Incidence of Atypical Femoral Fractures and Bisphosphonate Therapy
Clout, A., Narayanasamy, N., & Harris, I. A. (2016) · Journal of orthopaedic surgery · doi:10.1177/230949901602400110 · Cited by 12
The Management of Osteoporosis After Fragility Fracture
Morris, J., Karkenny, A. J., & Toro, J. B. (2017) · JBJS Reviews · doi:10.2106/jbjs.rvw.16.00098 · Cited by 12
The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines
Lagari, V. S., Gavcovich, T. B., & Levis, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.008 · Cited by 12
Management der Osteoporose nach Fragilitätsfrakturen
Gosch, M., Stumpf, U. C., Kammerlander, C., Böcker, W., Heppner, H.-J., & Wicklein, S. (2018) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1355-7 · Cited by 12
Orthopedic-Metabolic Collaborative Management for Osteoporotic Hip Fracture
Rotman‐Pikielny, P., Frankel, M., Lebanon, O. L. T., Yaacobi, E., Tamar, M., Netzer, D., Nabriski, D., Nyska, M., & Brin, Y. S. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0082 · Cited by 12
Clinical effect of early bisphosphonate treatment for pyogenic vertebral osteomyelitis with osteoporosis: An analysis by the Cox proportional hazard model
Kim, J., Jang, S. B., Kim, S. W., Oh, J.-K., & Kim, T.-H. (2018) · The Spine Journal · doi:10.1016/j.spinee.2018.08.014 · Cited by 12
Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
Iqbal, S. M., Qamar, I., Zhi, C., Nida, A., & Aslam, H. M. (2019) · Cureus · doi:10.7759/cureus.4146 · Cited by 12
Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate–Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study
Alarkawi, D., Ali, M. S., Bliuc, D., Pallarés, N., Tebé, C., Elhussein, L., Caskey, F. J., Arden, N., Ben‐Shlomo, Y., Abrahamsen, B., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3961 · Cited by 12
A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture
Hsu, C., Chen, H., Chen, H.-J., Chou, M.-Y., Wang, Y., Hsu, Y., Liang, C., & Chu, C. (2020) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2020.104021 · Cited by 12
Effects of Zoledronic Acid Treatment on Fracture Healing, Morbidity and Mortality in Elderly Patients with Osteoporotic Hip Fractures
Aslan, A., Sargın, S., Konya, M. N., & Gülcü, A. (2020) · Strategies in Trauma and Limb Reconstruction · doi:10.5005/jp-journals-10080-1439 · Cited by 12
Osteoporosis Diagnosis and Management
Pope, R. S., & Doback, J. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2020.09.009 · Cited by 13
Impact of bisphosphonates and comorbidities on initial hip fracture prognosis
Fu, T., Huang, T., Sun, C., Shyu, Y., & Chen, F. (2021) · Bone · doi:10.1016/j.bone.2021.116239 · Cited by 12
Medical management following an osteoporotic fracture
Orcel, P., & Funck‐Brentano, T. (2011) · Orthopaedics & Traumatology Surgery & Research · doi:10.1016/j.otsr.2011.10.002 · Cited by 12
Review article: Managing bone complications after kidney transplantation
Mainra, R., & Elder, G. J. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01156.x · Cited by 12
Physician Follow-up Care for Osteoporosis After Fragility Fractures
Giammattei, F., Giammattei, J., & Howland, V. (2009) · The Physician and Sportsmedicine · doi:10.3810/psm.2009.12.1743 · Cited by 12
OSTEOPOROSIS DIAGNOSIS AND TREATMENT
de Souza, M. P. G. (2010) · Revista Brasileira de Ortopedia (English Edition) · doi:10.1016/s2255-4971(15)30361-x · Cited by 12

Authors: Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
Affiliations: Veterans Health Administration (US)
University of Maryland, Baltimore (US)
McMaster University (CA)
Duke Medical Center (US)
Hvidovre Hospital (DK)
Oslo University Hospital (NO)
Savient Pharmaceuticals (United States) (US)
Novartis (Switzerland) (CH)
KU Leuven (BE)
ORCID: Magaziner, Jay S.
Adachi, Jonathan D.
Pieper, Carl F.
Nordsletten, Lars
Zhang, Jie
Mesenbrink, Peter
Eriksen, Erik Fink
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11
Volume: 357
Issue: 18
Pages: 1799-1809
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa074941
PMC: PMC2324066
OpenAlex: W2163830908
Cited by: 2,003
References: 35
Citations by year: 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
FWCI: 160.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
PubMed Central (acceptedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Savient Pharmaceuticals
Novo Nordisk
Servier
National Institute on Aging (K23AG024787)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords: zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks